Zanubrutinib
BGB-3111-215
Phase 2 small_molecule completed
Quick answer
Zanubrutinib for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma is a Phase 2 program (small_molecule) at BeOne Medicines with 1 ClinicalTrials.gov record(s).
Program details
- Company
- BeOne Medicines
- Indication
- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed